As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Common types of neuroendocrine pancreatic cancer ... There are several chemotherapy regimens for treating pancreatic cancer. Most people receive two or more of the following chemo drugs ...

Pancreatic enzyme replacement therapy (Pert) provides the enzymes people affected by pancreatic cancer need to absorb ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

and the potential treatment of SCLC and neuroendocrine tumors. These forward-looking statements may contain words such as “aim,” “anticipate,” “believe,” “could,” “estimate ...

Evidence for chemotherapy ... for breast cancer or androgen ablation for prostate cancer. The effects of chemotherapy-associated cardiovascular toxicity and alterations in neuroendocrine function ...

total of 218 consecutive patients with pathologically confirmed neuroendocrine ... resection after chemotherapy is still alive after 15.2 months without evidence of tumor recurrence.

These patients have an urgent need for innovative treatment ... neuroendocrine tumours and associated with poor clinical outcomes. SCLC represents almost 15% of the 2.5 million annual lung cancer ...

SCLC represents almost 15% of the 2.5 million annual lung cancer diagnoses globally ... who have previously undergone a minimum of one platinum-based chemotherapy regimen. It is being assessed both as ...